A Schedule III registration from the federal government “does not replace” Missouri’s medical cannabis laws forbidding interstate commerce or other activities, state regulators warned its licensees on Nov. 9.
The Missouri Division of Cannabis Regulation (DCR) issued this new guidance on federal rescheduling 10 days after the U.S. Drug Enforcement Administration (DEA) approved its first batch of Schedule III registrations for state-licensed medical cannabis businesses.
“The recent federal rescheduling of state-licensed medical marijuana does not replace Missouri’s medical marijuana regulatory program,” DCR officials told licensees in Monday’s message. “Instead, it adds federal requirements on top of the existing state framework, creating a dual-layer system in which licensees must comply with both Missouri regulations and applicable federal obligations, if the licensee chooses to register with the DEA.”
The DEA’s initial registrations granted Schedule III status to more than 900 dispensaries across seven medical-only cannabis states, with U.S. Attorney General Todd Blanche proclaiming that Americans “deserve access to the best medical treatments in the world” in an Oct. 30 announcement.
While 209 Missouri cannabis businesses applied through the DEA’s expedited registration process following Blanche’s April 2026 rescheduling order, including 156 dispensaries, 18 distributors and 35 manufacturers, none were included in the initial registrations, as Missouri is among the 24 states that have legalized both adult-use and medical cannabis nationwide.
Overall, nearly 7,000 state-licensed medical cannabis businesses nationwide applied for the expedited registration process.
Also on Oct. 30, the Minnesota Star Tribune reported that the DEA may reject all of Minnesota’s 30 expedited applicants, citing a DEA notification that Minneapolis-based In-Dispensary received that morning denying its registration application because it serves both adult-use customers and medical patients, which the denial notification indicates “fails to provide ‘robust’ protections against diversion” and conflicts with federal law.
The news outlet’s reporting was unclear whether other Minnesota businesses received the same denial notification or whether other states with dual adult-use and medical licensure may face similar circumstances, such as Missouri.
Regardless, Missouri’s cannabis regulators told its licensees on Monday that DEA registration “now functions as the formal link” between the state’s cannabis program and the U.S. Controlled Substances Act.
“Missouri licensees must continue operating exactly as they do today under state authority,” DCR officials told licensees. “Federal registration is dependent on maintaining state licensure. Therefore, where any potential conflict arises between state and federal expectations, it is imperative licensees work with the Department to ensure they remain in compliance with laws and regulations governing their state license.”
The DCR, which operates within the Missouri Department of Health and Senior Services (DHSS), provided the example of state law currently forbidding interstate cannabis commerce, advising licensees that should they receive authorization to import or export cannabis under a Schedule III federal registration, exercising that authority before Missouri potentially updates its state laws would jeopardize their licensure – a requirement to maintain DEA registration status.
While one advantage of obtaining a Schedule III registration is the allowance for businesses to deduct ordinary expenses under Section 280E of the Internal Revenue Code, other possible benefits include potential access to export licenses and interstate commerce, as well as compliance with banking, exchange listings, credit facilities and/or business mergers.
“Licensees should ensure their operations remain fully within authorized state activities as they prepare for future federal compliance requirements,” DCR told licensees.
To remain compliant, the division reminded state operators to adhere to:
- All product tracking requirements in the statewide track-and-trace system;
- State testing standards, including laboratory certification requirements and compliance with DHSS-approved methodologies; and
- Visitor and facility access rules, including sign-in procedures, restricted areas and escorted access.
The DCR also advised licensees to apply the state’s existing visitor rules to DEA agents entering their facilities, and to treat their inspections as any other official regulatory visit.
“Under Missouri regulations, DEA agents may enter licensed Missouri facilities for legitimate business purposes, including inspections, audits or diversion investigations,” DCR officials said. “Agents must present proper credentials.
The division also advised licensees to “protect confidential information from unauthorized disclosure,” per state laws and regulations, and to review House Bill 2641, legislation that established the “Intoxicating Cannabinoid Control Act,” which places all hemp-derived cannabinoid products into the state’s definition of “marijuana.”
The legislation also contains new confidentiality provisions that go into effect on Nov. 11, 2026.
But foremost, the DCR stressed the importance of Missouri’s intrastate cannabis program, providing the definitions of unlawful diversion and inversion.
“Although [Blanche’s] final order amends federal regulations to allow DEA registrants to receive authorization for Schedule III marijuana products, Missouri regulations do not yet include a framework either for import or export of cannabis or for transport of cannabis across state lines,” regulatory officials told licensees.
